都市激情在线亚洲国产91_欧美日韩国产国语对白_av成人毛片在线免费观看_少妇爆乳无码专区网站_亚洲Aⅴ无码吞精久久AV_亚洲AV毛片一区无码日韩_国产成人精品1024视频网站_最新综艺节目国产精品喷浆_国产在线拍揄自揄视频网站_天天少妇被猛烈进入在线播放

In 2020, as Kexing Biopharm overcame the impact of COVID-19 and insisted on stable operation, it achieved a revenue of RMB 1.22 billion, net profit of RMB 139 million and net cash flow of RMB 106 million. Then, it kept enhancing the exploration of sales terminals and promoting fine market channels management. By 2020, Kexing Biopharm's products have been adopted by more than 16,000 sales terminals in China, including more than 6,000 hospitals, and have been registered in, exported and sold to more than 30 countries. Kexing Biopharm has achieved a sustained increase in R&D investment, up 30.20% year-on-year, accelerated the layout of innovative drug projects, and made steady progress in ongoing projects. Finally, it was listed on the Sci-Tech Innovation Board in the A-share market (stock code: 688136), which was deemed as a new historic leap.